Has CJC-1295 been compared directly with tesamorelin?

No direct clinical comparison is established by the cited studies. Their populations and endpoints differ, so a treatment ranking cannot be inferred.

What did the CJC-1295 human studies measure?

Short randomized studies in healthy adults measured growth hormone, IGF-1, pharmacokinetics and short-term tolerability; they did not establish clinical benefit for fat loss or aging.

CJC-1295 vs Tesamorelin: Evidence and Approval

Q: What is tesamorelin approved to treat?

FDA labeling indicates tesamorelin for reducing excess abdominal fat in adults with HIV and lipodystrophy. It is not indicated for weight-loss management.

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

What the evidence compares

Both compounds act through the growth hormone-releasing hormone pathway, but shared mechanism does not make their clinical evidence interchangeable. Tesamorelin has an FDA-approved indication for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its pivotal randomized trial measured visceral adipose tissue (VAT) by imaging. The label says it is not indicated for weight-loss management, and long-term cardiovascular safety is unestablished. FDA prescribing information; Falutz et al., 2007, PMID 18057338.

CJC-1295 was studied in two short randomized, placebo-controlled ascending-dose studies in healthy adults. Growth hormone and IGF-1 rose, but these are hormone biomarkers, not evidence of a patient benefit or an approved indication. The investigators reported no serious adverse reactions in those small, brief studies; that does not establish long-term safety. Teichman et al., 2006, PMID 16352683.

Question	CJC-1295	Tesamorelin
Human evidence cited here	Short healthy-volunteer hormone and pharmacokinetic studies	Randomized trials in adults with HIV and excess abdominal fat
Clinical endpoint established here	None	Reduction in VAT in the indicated population
FDA product status	No approved CJC-1295 product identified in the cited FDA review	Approved for the labeled excess-abdominal-fat indication
Evidence grade for the stated outcome	Low for clinical benefit; hormone response observed	High for VAT reduction in the indicated population, not for general weight loss or longevity

FDA’s CJC-1295 safety review describes limited clinical data and reports of increased heart rate and systemic vasodilatory reaction with compounded products. A compounding review is not a drug approval. FDA compounding safety review.

No cited trial directly compares the two compounds or validates their combined use. Relative hormone changes cannot establish relative clinical efficacy or safety.

Educational comparison only; not medical advice.

CJC-1295 vs Tesamorelin

CJC-1295

Tesamorelin

What the evidence compares

View Full Dossiers

Stay Updated on Peptide Comparisons